A clinical briefing on the Amicar (Aminocaproic Acid) shortage for providers: timeline, prescribing implications, alternatives, and patient tools.
If your patients are reporting difficulty filling Aminocaproic Acid prescriptions, they're not wrong. The supply landscape for this antifibrinolytic agent has been disrupted since 2023, and while the situation has stabilized for some formulations, gaps persist — particularly for the oral solution. This briefing covers what you need to know to keep your patients treated.
Understanding how we got here helps inform prescribing decisions going forward:
The supply situation creates several practical considerations for prescribers:
Oral tablets (500 mg, 1,000 mg) are the most reliably available formulation. If your patient is currently on the oral solution and can safely transition to tablets, this may resolve their access issue. For pediatric patients or those with swallowing difficulties who require a liquid formulation, consider:
Standard dosing for acute fibrinolytic bleeding: 5 g loading dose orally during the first hour, followed by 1 to 1.25 g/hour to maintain effective plasma concentrations. Maximum: 30 g/day. Duration is typically 8 hours or until bleeding control is achieved. Dose adjustment is required in renal impairment, as aminocaproic acid is primarily renally cleared (elimination half-life approximately 2 hours in normal renal function).
If Aminocaproic Acid is truly unavailable for your patient, the most clinically appropriate substitution is Tranexamic Acid (TXA). Key considerations:
For patients with mild hemophilia A or von Willebrand disease, Desmopressin (DDAVP) remains an appropriate option, particularly for procedural prophylaxis. Desmopressin increases Factor VIII and von Willebrand factor levels and can be used alone or in combination with an antifibrinolytic.
For detailed alternative comparisons, see our clinical overview: Alternatives to Amicar.
| Formulation | Status (Early 2026) | Notes |
|---|---|---|
| Oral Tablets 500 mg | Generally Available | Multiple generic manufacturers; may require pharmacy special order |
| Oral Tablets 1,000 mg | Generally Available | Same as above |
| Oral Solution 250 mg/mL | Limited | Reduced suppliers after Akorn/Vistapharm exits; compounding may be needed |
| IV Injection 250 mg/mL | Available (Hospital) | Pfizer and others supply; periodic institutional shortages |
Cost can be a significant barrier for patients, particularly those without insurance or with high-deductible plans:
There is no dedicated manufacturer savings program or copay card for Aminocaproic Acid. For patients facing financial hardship, third-party resources include:
Always recommend that patients compare prices with discount coupons before filling. The difference between retail and coupon price can exceed $200. For savings strategies to share with patients, see how to save money on Amicar.
Medfinder for Providers offers real-time pharmacy stock checking for Aminocaproic Acid and other hard-to-find medications. You can use it to:
Additional resources:
The Aminocaproic Acid market is unlikely to see significant new entrants given the small patient population and relatively low margin. Providers should plan for continued intermittent availability challenges, particularly for the oral solution. Practical steps for your practice:
The Aminocaproic Acid supply picture is manageable but requires proactive attention. Tablets remain generally accessible, the oral solution needs creative sourcing, and Tranexamic Acid is a reliable therapeutic backup. By using tools like Medfinder for Providers and staying current on shortage updates, you can minimize disruptions to your patients' care.
For related clinical content, see:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
